» Articles » PMID: 32138748

Quantifying the Economic Cost of Antibiotic Resistance and the Impact of Related Interventions: Rapid Methodological Review, Conceptual Framework and Recommendations for Future Studies

Overview
Journal BMC Med
Publisher Biomed Central
Specialty General Medicine
Date 2020 Mar 7
PMID 32138748
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Antibiotic resistance (ABR) poses a major threat to health and economic wellbeing worldwide. Reducing ABR will require government interventions to incentivise antibiotic development, prudent antibiotic use, infection control and deployment of partial substitutes such as rapid diagnostics and vaccines. The scale of such interventions needs to be calibrated to accurate and comprehensive estimates of the economic cost of ABR.

Methods: A conceptual framework for estimating costs attributable to ABR was developed based on previous literature highlighting methodological shortcomings in the field and additional deductive epidemiological and economic reasoning. The framework was supplemented by a rapid methodological review.

Results: The review identified 110 articles quantifying ABR costs. Most were based in high-income countries only (91/110), set in hospitals (95/110), used a healthcare provider or payer perspective (97/110), and used matched cohort approaches to compare costs of patients with antibiotic-resistant infections and antibiotic-susceptible infections (or no infection) (87/110). Better use of methods to correct biases and confounding when making this comparison is needed. Findings also need to be extended beyond their limitations in (1) time (projecting present costs into the future), (2) perspective (from the healthcare sector to entire societies and economies), (3) scope (from individuals to communities and ecosystems), and (4) space (from single sites to countries and the world). Analyses of the impact of interventions need to be extended to examine the impact of the intervention on ABR, rather than considering ABR as an exogeneous factor.

Conclusions: Quantifying the economic cost of resistance will require greater rigour and innovation in the use of existing methods to design studies that accurately collect relevant outcomes and further research into new techniques for capturing broader economic outcomes.

Citing Articles

Economic Evaluation of Interventions to Reduce Antimicrobial Resistance: A Systematic Literature Review of Methods.

Aluzaite K, Soares M, Hewitt C, Robotham J, Painter C, Woods B Pharmacoeconomics. 2025; .

PMID: 40048093 DOI: 10.1007/s40273-024-01468-7.


Antimicrobial resistance in Malaysia: a cross-sectional study analysing trends and economic impacts.

Ar M, Binti Wan Puteh S, Ibrahim R, Rahman M, Abdul Karim Z, Bin Ali F BMJ Open. 2025; 15(2):e091687.

PMID: 39947822 PMC: 11831257. DOI: 10.1136/bmjopen-2024-091687.


Incremental cost of treating antimicrobial-resistant infections among hospitalised patients in India: a cohort study.

Kadam A, Mamulwar M, Bhambure G, Bembalkar S, Bapat S, Mane A BMJ Open. 2025; 14(12):e086505.

PMID: 39806697 PMC: 11664386. DOI: 10.1136/bmjopen-2024-086505.


Derivation of a risk-adjusted model to predict antibiotic prescribing among hospitalists in an academic healthcare network.

Onwubiko U, Mehta C, Wiley Z, Jacob J, Ashley Jones K, Kubes J Antimicrob Steward Healthc Epidemiol. 2024; 4(1):e163.

PMID: 39411663 PMC: 11474874. DOI: 10.1017/ash.2024.422.


Overcoming challenges in the economic evaluation of interventions to optimise antibiotic use.

Roope L, Morrell L, Buchanan J, Ledda A, Adler A, Jit M Commun Med (Lond). 2024; 4(1):101.

PMID: 38796507 PMC: 11127962. DOI: 10.1038/s43856-024-00516-9.


References
1.
Smith R, Coast J . The true cost of antimicrobial resistance. BMJ. 2013; 346:f1493. DOI: 10.1136/bmj.f1493. View

2.
Phodha T, Riewpaiboon A, Malathum K, Coyte P . Excess annual economic burdens from nosocomial infections caused by multi-drug resistant bacteria in Thailand. Expert Rev Pharmacoecon Outcomes Res. 2018; 19(3):305-312. DOI: 10.1080/14737167.2019.1537123. View

3.
Sandmann F, Robotham J, Deeny S, Edmunds W, Jit M . Estimating the opportunity costs of bed-days. Health Econ. 2017; 27(3):592-605. PMC: 5900745. DOI: 10.1002/hec.3613. View

4.
Asche C, McAdam-Marx C, Seal B, Crookston B, Daniel Mullins C . Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance. J Antimicrob Chemother. 2008; 61(5):1162-8. DOI: 10.1093/jac/dkn073. View

5.
Bratzler D, Dellinger E, Olsen K, Perl T, Auwaerter P, Bolon M . Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt). 2013; 14(1):73-156. DOI: 10.1089/sur.2013.9999. View